The FDA said today that it had approved dulaglutide, Lilly's once-weekly injection to control blood sugar in adults with type 2 diabetes. The drug will be marketed under the brand name of Trulicity. The FDA said that the safety and efficacy of Trulicity, a glucagon-like peptide-1 (GLP-1) receptor agonist, had been studied [...]